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Background: There are no prior studies that have estimated the risk of upper gastrointestinal bleeding (UGIB)
among the dialysis population relative to the general population. The aim of this study was to examine the risk of
UGIB among end-stage renal disease (ESRD) patients during a 6-year period following their initiation of
hemodialysis (HD) therapy in Taiwan- a country with the highest incidence of ESRD in the world, using general
population as an external comparison group.
Methods: Data were obtained from the Taiwan National health Insurance Research Database. In total, 796 patients
who were beginning HD between 1999 and 2003 were recruited as the study cohort and 3,184 patients matched
for age and sex were included as comparison cohort. Multivariate Cox proportional hazard regression models were
used to adjust for confounding and to compare the 6-year UGIB-free survival rate between these two cohorts.
Results: The incidence rate of UGIB (42.01 per 1000 person-year) was significantly higher in the HD cohort than in
the control cohort (27.39 per 1000 person-years). After adjusting for potential confounders, the adjusted hazard
ratios for UGIB during the 6-year follow-up periods for HD patients was 1.27 (95% CI=1.03-1.57) compared to
patients in the comparison cohort.
Conclusions: We conclude that HD patients were at an increased risk for UGIB compared with the general
population.
Keywords: Upper gastrointestinal bleeding, End-stage renal disease, Cohort studyBackground
The increasing number of patients with end-stage renal
disease (ESRD) requiring dialysis therapy is becoming a
worldwide public health problem and puts a substantial
burden on health care resources. Taiwan is also con-
fronting this severe challenge [1]. The incidence and
prevalence of ESRD in Taiwan were not only the highest
of some 30 countries reported by USRDS, but were 2–4
times higher than most European countries [2]. There
have been 2.6- and 3.7-fold increases in incidence and
prevalence during the past decade in Taiwan, respect-
ively [1]. The financial burden of dialysis has exceeded* Correspondence: chunyuh@kmu.edu.tw
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reproduction in any medium, provided the orthe expenditure on all cancers combined, and reducing
the number of people with ESRD constitutes a national
health priority in Taiwan [3].
Studies suggest that acute gastrointestinal hemorrhage,
especially upper gastrointestinal bleeding (UGIB), is the
most frequent bleeding complication of acute renal fail-
ure (ARF), even though the reported incidence ranges
widely [4]. Reports also suggest that the prevalence or
incidence of UGIB in patients with ESRD may be greater
than that in the general population [5-10]. It has been
estimated that UGIB accounts for 3 to 7% of all deaths
among ESRD patients [5]. However, some studies found
that patients with chronic renal failure are not at risk for
developing chronic peptic ulcers [11,12]. Most of the
previous studies were conducted in western countries
[5,6,8,10-12] and were done before the era of extensive. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tinal stress lesions in critically ill patients [4].
To date, there are limited data regarding the occurrence
of UGIB in dialysis patients. Most of the above-mentioned
epidemiologic studies suffer from methodological limita-
tions such as a relatively small size, case series without
controls or not taking potential confounders into conside-
rations in the regression model. With these methodo-
logical issues in mind, we conducted a cohort study using
general population as an external comparison group to
determine the risk of UGIB among ESRD patients during
a 6-year period following their initiation of hemodialysis
(HD) therapy in Taiwan- a country with the highest inci-
dence of ESRD in the world. To our knowledge, this is the
first population-based cohort study to investigate the
relationship between HD and the risk of UGIB.
Methods
Data source
The National Health Insurance (NHI) program, which pro-
vides compulsory universal health insurance, was imple-
mented in Taiwan on March 1, 1995. Under the NHI, 98%
of the island’s population receives all forms of health care
services including outpatient services, inpatient care,
Chinese medicine, dental care, childbirth, physical therapy,
preventive health care, home care, and rehabilitation for
chronic mental illness. In cooperation with the Bureau
of NHI, the National Health Research Institute (NHRI) of
Taiwan randomly sampled a representative database of
1,000,000 subjects from the entire NHI enrollees by means
of a systematic sampling method for research purposes.
There were no statistically significant differences in age,
gender, and healthcare costs between the sample group
and all enrollees, as reported by the NHRI. This dataset
(from January 1996 to December 2009) includes all claim
data for these 1,000,000 subjects, offers a good opportunity
to examine the risk of UGIB occurring among patients
with ESRD. These databases have previously been used for
epidemiological research, and information on prescription
use, diagnoses, and hospitalizations has been shown to be
of high quality [1,13-15].
Because the identification numbers of all individuals
in the NHRI databases were encrypted to protect the
privacy of the individuals, this study was exempt from
full review by the Kaohsiung Medical University Institu-
tion Review Board.
Study cohorts
From this database, we selected all patients who were be-
ginning chronic HD or peritoneal dialysis between January
1, 1999 and December 31, 2003 and who have survived
more than 90 days of renal replacement therapy for ESRD
(n=1046) [16]. We excluded individuals younger than 18
years of age because they were not at appreciable risk ofUGIB and in order to limit the study subjects to an adult
population (n=9). ESRD patients are defined as those who
had catastrophic illness registration cards for ESRD
(ICD-9-CM code 585) and started renal replacement ther-
apy. In Taiwan, patients who reached ESRD with the need
for long-term renal replacement therapy can apply for
catastrophic illness registration cards given by the Bureau
of Health Insurance. These patients do not need to pay
copayments when they seek health care for renal disease.
A detailed description of this cohort is published else-
where [17]. We excluded subjects with any type of UGIB
diagnosed before or within 90 days of their index ambula-
tory care visit (the date of a patient’s initiating dialysis)
(n=169). In addition, we also excluded those subjects who
received a renal transplant (n=3) or peritoneal dialysis
(n=57). A total of 808 incident HD patients were identified
between January 1, 1999 and December 31, 2003.
The comparison cohort were selected from the re-
maining patients in the database. We first excluded
patients who had been diagnosed with chronic kidney
disease (ICD-9 CM codes 250.4*, 274.1*, 283.11, 403.*1,
404.*2, 404.*3, 440.1, 442.1, 447.3, 572.4, 580–588, 642.1*,
646.2*) [1] during the period 1996–2009 and those
younger than 18 years of age. For each study cohort pa-
tient, 4 reference subjects were identified randomly and
matched for gender, age (birth of year), and the year of
index ambulatory care visit. For the comparison cohort,
the index ambulatory care visit was their first ambula-
tory care visit occurring in the index year. In addition,
we excluded patients who had been diagnosed with
UGIB before or within 90 days of their index ambulatory
care visits. Of the 808 incident HD cases ascertained, no
controls could be found for 12 of the cases. A total of
3,184 subjects served as a comparison cohort group.
Incidence of UGIB
Patients were considered to have experienced UGIB if
a hospital discharge diagnosis indicating UGIB, as de-
fined by any one of the gastric, duodenal, peptic, and
gastrojejunal bleeds were reported (ICD-9-CM codes
531.0X, 531.2X, 531.4X, 531.6X, 532.00, 532.2X, 532.4X,
532.6X, 533.0X, 533.2X, 533.4X, 533.6X, 534.0X, 534.2X,
534.4X, 534.6X, 535.X1). Gastrointestinal bleed, unspeci-
fied, was not used to identify UGIB because it was felt to
be too nonspecific with regard to location of bleeding.
Potential confounders
For all individuals in both cohorts, we obtained data on
potential confounders which are documented risk factors
for UGIB, including hypertension (ICD-9-CM, codes
401–405), diabetes (ICD-9-CM, code 250), hyperlipid-
emia (ICD-9-CM, code 272), coronary heart disease
(ICD-9-CM, codes 410–414), chronic liver disease and
cirrhosis (ICD-9-CM, code 571), and Helicobacter pylori
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index ambulatory care visit. In addition, we also ob-
tained prescription data for medications for aspirin,
non-steroidal antiinflammatory drugs (NSAIDs), H2 re-
ceptor antagonists (H2RA), and proton pump inhibitor
(PPI) use, recorded between the index date to the date
of UGIB hospitalization, death or the end of the study.
We collected the date of prescription, the daily dose,
and the number of days supplied. The defined daily
doses (DDDs) recommended by the WHO were used to
quantify the usage of medications [18].Table 1 Basic characteristics for hemodialysis patients







n % n %
Gender
Male 365 45.85 1460 45.85 -
Female 431 54.15 1724 54.15
Age (mean±SD) 56.72±13.75 56.72±13.74 -
< 50 241 30.28 964 30.28 0.99
50-64 296 37.19 1184 37.19
65-74 200 25.13 798 25.06
> 74 59 7.41 238 7.47
Hypertension
Yes 566 71.11 1032 32.41 < 0.001
No 230 28.89 2152 67.59
Diabetes
Yes 288 36.18 395 12.41 < 0.001
No 508 63.82 2789 87.59
Coronary heart disease
Yes 162 20.35 372 11.68 < 0.001
No 634 79.65 2812 88.32
Hyperlipidemia
Yes 145 18.22 446 14.01 0.003
No 651 81.78 2738 85.99
Liver cirrhosis
Yes 20 2.51 33 1.04 0.001
No 776 97.49 3151 98.96
HP eradication
Yes 54 6.78 201 6.31 0.627
No 776 97.49 3151 98.96
Aspirin use (gm/person-year) 11.28±35.76 13.05±47.29 0.247
NSAIDs use (DDDs/person-year) 14.72±29.54 41.99±75.14 < 0.001
PPI use (DDDs/person-year) 16.15±184.80 3.02±16.39 < 0.001
H2RAs use (DDDs/person-year) 6.97±21.30 5.60±18.44 0.490Statistics
For comparisons of proportions between the study and
comparison cohorts, the chi-square test was used. The
mean doses of medication use (aspirin, NSAIDs, H2RA,
and PPI) were calculated and compared between the
study and comparison cohorts using paired t test; be-
cause of the skew distribution of these medication use
data, medication use data were log-transformed to
improve normality. For the analysis, the subjects were
categorized into one of the three exposure categorizes:
nonusers (subjects with no prescription at any time
between the index date and the date of UGIB hos-
pitalization, death or the end of the study), and users of
doses equal to or below the mean, and users of doses
above the mean based on the distribution of use among
controls. Each patient was individually tracked for a
6-year period starting from the index ambulatory care
visit to identify whether the patient had experienced
UGIB during the follow-up period. The person-years of
follow-up were calculated for each patient from the date
of the index ambulatory care visit to the date of UGIB
hospitalization, death or the end of the study (a 6-year
follow-up period), whichever occurred first. Incidence
rates were calculated by dividing the number of UGIB
hospitalizations by the total person-years of follow-up.
Kaplan-Meier curves and log-rank tests were used to
explore the difference in the risk of developing UGIB
between the 2 cohorts. A multivariate frailty Cox pro-
portional hazards regression model, which incorporates
an unmeasured “random” effect (the frailty) in the
hazard function, was used to estimate the hazard ratios
(HR) and 95% confidence intervals (CI) adjusted for the
above-mentioned potential confounders [19]. The ass-
umption of proportional hazards was assessed by includ-
ing an interaction term between time and exposure (HD
patients vs patients in the comparison cohort) in the
model, and the proportional assumption was satisfied.
Analyses were performed using the SAS statistical pack-
age (version 9.2, SAS Institute Inc., Cary, NC, USA). All
statistical tests were two-sided. Values of p < 0.05 were
considered statistically significant.Results
There were 796 patients in our HD cohort that were
compared with 3,184 selected matched controls. Table 1
presents the distribution of demographic characteristics
and selected medical conditions of the study subjects. Of
the 3,980 patients sampled, the mean age was 56.72 years
(SD=13.74), with means of 56.72 (SD=13.75) and 56.72
(SD=13.74) for HD patients and comparison patients,
respectively. HD patients had a significant higher rate of
hypertension, diabetes, hyperlipidemia, coronary heart dis-
ease, and liver cirrhosis. HD patients were also signifi-
cantly more likely to have PPI use.
Table 3 Adjusted hazard ratio (HRs) for UGIB among the
sampled patients identified by Cox regression analysis
Variable Adjusted HR (95% CI)a
Patients receiving HD 1.27 (1.03-1.57)
Hypertension 1.13 (0.91-1.39)
Diabetes 1.09 (0.86-1.39)
Coronary heart disease disease 1.14 (0.88-1.49)
Hyperlipidemia 1.14 (0.88-1.46)
Liver cirrhosis 1.14 (0.59-2.20)
Medication use
NSAIDs (per 1 DDD increase) 1.00 (0.99-1.00)
PPI (per 1 DDD increase) 1.01 (1.00-1.01)



























Figure 1 UGIB-free survive rates for HD patients and patients in
the comparison cohort.
Table 2 Crude hazard ratios of UGIB in hemodialysis
cohort compared to patients in comparison cohort






No. of UGIB 176 471
Person time (years) 4189.06 17196.73
Incidencea 42.01 27.39
Crude HR (95% CI) 1.50
(1.25-1.80)
1.00
No. of gastric ulcer 68 144
Person time (years) 4189.06 17196.73
Incidencea 16.23 8.37
Crude HR (95% CI) 1.86
(1.37-2.51)
1.00
No. of duodenal ulcer 26 86
Person time (years) 4189.06 17196.73
Incidencea 6.21 5.00
Crude HR (95% CI) 1.21
(0.77-1.90)
1.00
No. of peptic ulcer 50 160
Person time (years) 4189.06 17196.73
Incidencea 11.94 9.30
Crude HR (95% CI) 1.24
(0.89-1.72)
1.00
No. of gastrojejunal ulcer 2 10
Person time (years) 4189.06 17196.73
Incidencea 0.48 0.58
Crude HR (95% CI) 0.94
(0.20-4.44)
1.00
No. of gastritis/duodenitis with bleeding 30 71
Person time (years) 4189.06 17196.73
Incidencea 7.16 4.13
Crude HR (95% CI) 1.74
(1.12-2.70)
1.00
a per 1000 person-years.
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6-year follow-up periods for these two cohorts. Of the
total 3,980 sampled patients, 647 patients (16.26%)
developed UGIB throughout the study periods, 176
(22.11% of the HD patients) from the study cohort (with
an incidence rate of 42.01 per 1,000 person-years) and
471 (14.79%) from the comparison cohort (with an inci-
dence rate of 27.39 per 1,000 person-years). Gastric
ulcers were found to be the most common source of
bleeding (16.23 per 1000 person-years), while bleeding
resulting from a gastrojejunal ulcer was least frequent
(0.48 per 1000 person-years) among HD patients.
After adjusting for age, gender, hypertension, diabetes,
hyperlipidemia, coronary heart disease, liver cirrhosis,the use of NSAIDs, and PPI, Cox multivariate hazard
regression analysis showed that the hazard of UGIB dur-
ing the 6-year follow-up periods was 1.27 times greater
(95% CI=1.03-1.57) for patients treated with hemodialysis
than for the comparison cohort (Table 3; Figure 1).
Discussion
The only study estimating the incidence of UGIB in
dialysis patients is performed in the United States, which
reported an incidence rate of 22.77 per 1000 person-
years [10]. The incidence of UGIB was 42.01 per 1000
person-years in the present study. The reason for a
higher incidence rate of UGIB in Taiwanese HD patients
are not clear. It may be that renal transplant recipients
and peritoneal dialysis patients were excluded in the
present study and that renal transplant recipients and
peritoneal dialysis patients had a lower risk of UGIB
compared to HD patients [10]. However, the possibility
that the incidence rates of UGIB in Taiwanese popula-
tion are higher than that of the United States and that
characteristics of HD patients are substantially different
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ther study is needed to clarify the reason.
There are no prior studies that have estimated the risk
of UGIB among the dialysis population relative to the
general population. Previous study has only used dialysis
patients as a cohort to identify patient characteristics
associated with the incident UGIB without seeking a
comparison group [10]. Because of the uniqueness of the
exposure (hemodialysis), special exposure cohort (HD
patients) provides a statistically efficient way of studying
this factor, which would be rare in general cohort. Spe-
cial exposure cohort (dialysis patients), however, require
an external comparison group. To the best of our know-
ledge, this study is among the first matched cohort study
to examine the risk of UGIB among HD patients using
general population as an external comparison group
(with a age- and gender-matched comparison group). In
this population-based cohort study, after adjusting for
potential confounders, we found that HD patients were
1.27 times more likely than the general population to
experience UGIB during the 6-year follow-up period.
Our findings support previous studies that found
chronic renal failure can be a UGIB risk factor.
The major strength of our study is the use of a compu-
terized database, which is population based and is highly
representative and allows a clear observation of the
temporal relationship between HD and UGIB. Because we
included a national sample of ESRD patients initiating HD
therapy between January 1, 1999 and December 31, 2003,
and because the control subjects in this study were
selected from a simple random sampling of insured gen-
eral population, we can rule out the possibility of selection
bias. Moreover, the large sample size affords considerable
statistical power for detecting real difference between the
two cohorts.
Several limitations of the present study should be noted.
First, diagnoses of ESRD, UGIB, or any other comorbid
medical conditions and prescription information rely on
administrative claims data may be less accurate than those
obtained according to standardized criteria and misclassi-
fication is possible. However, from previous studies, the
NHIRD is of acceptable quality to provide reasonable
estimations for epidemiological data [13-15]. Moreover,
regular chart-review and cross-checking mechanisms
conducted by Taiwan’s NHI Bureau do facilitate the accur-
acy of coding [20]. Second, although we adjusted for
several potential confounders in the statistical analysis, a
number of possible confounding variables, including
smoking [21], alcohol use [22], physical inactivity [21,23],
and Helicobacter pylori infection [24], which might be
associated with UGIB development were not included in
our database. These unmeasured risk factors might have
biased results if they were differentially associated with
case versus comparison cohort. Third, we were not able tocontact the patients directly about their use of medica-
tions because of anonymization of their identification
number. Using pharmacy records representing dispensing
data rather than usage data might have introduced an
overestimation of medication use. Fourth, the case cohort
includes only HD patients. It has been hypothesized that
intermittent anticoagulation may place HD patients at
greater risk for UGIB. If this were the case, one would
anticipate that peritoneal dialysis and renal transplantation
would be associated with a lower risk for UGIB compared
to HD [10]. Therefore, the results of this study may not be
generalizable to patients receiving peritoneal dialysis or
renal transplantation.
Conclusion
In summary, our study results provide evidence that HD
patients are at an increased risk for UGIB compared
with general population. Therefore, prevention of UGIB
is becoming an important issue in the maintenance of
good quality of life for HD patients.
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